Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Shrugs Off COVID Antibody’s Inferiority In Therapy Setting, Sees Prevention As Main Role

Injection Cut Risk By 50%

Executive Summary

AstraZeneca’s anti-SARS-CoV-2 antibody product is unlikely to rival Regeneron or Vir/GSK’s offerings in mild-to-moderate patients, where Merck’s newly-submitted oral molnupiravir will also change treatment.

You may also be interested in...



Coronavirus Update: Pfizer/BioNTech Vaccine Effective Against Omicron

Also, AstraZeneca scores an emergency use authorization from the FDA for its COVID-19 PrEP antibody Evusheld, while Merck files for Japanese approval of molnupiravir.

Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market

Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.

AstraZeneca COVID-19 Antibody Could Be Solution For Vulnerable But Not Vaccine Alternative

AZD7442 can provide antibodies in people who cannot generate their own after vaccination but could in theory also be used to protect other groups, including unvaccinated populations.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel